<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="9541"><DrugName>OM-89</DrugName><DrugNamesKey><Name id="42773890">Subreum</Name><Name id="42759781">UroVaxom</Name><Name id="42773891">UroVaxon</Name></DrugNamesKey><DrugSynonyms><Name><Value>UroVaxom</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>OM-89</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>OM-8980</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>Subreum</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>UroVaxon</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18671">OM Pharma</CompanyOriginator><CompaniesPrimary><Company id="16268">Vifor Pharma Ltd</Company><Company id="1037068">China Medical System Holdings Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="18671">OM Pharma</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9541" type="Drug"><TargetEntity id="122672" type="siDrug">OM-89</TargetEntity></SourceEntity><SourceEntity id="1037068" type="Company"><TargetEntity id="4295863681" type="organizationId">China Medical System Holdings Ltd</TargetEntity></SourceEntity><SourceEntity id="16268" type="Company"><TargetEntity id="5035523654" type="organizationId">Vifor SA</TargetEntity></SourceEntity><SourceEntity id="18671" type="Company"><TargetEntity id="4297456469" type="organizationId">Om Pharma SA</TargetEntity></SourceEntity><SourceEntity id="1798" type="ciIndication"><TargetEntity id="10054088" type="MEDDRA"/></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="473" type="ciIndication"><TargetEntity id="N41" type="ICD10"/><TargetEntity id="10036978" type="MEDDRA"/><TargetEntity id="D011472" type="MeSH"/><TargetEntity id="-636590603" type="omicsDisease"/><TargetEntity id="363" type="siCondition"/></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Bacterial urinary tract infection - Germany - Dec-1992</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1798">Bacterial urinary tract infection</Indication><Indication id="291">Rheumatoid arthritis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="20">Pain</Indication><Indication id="473">Prostatitis</Indication></IndicationsSecondary><ActionsSecondary><Action id="1594">Antibacterial</Action><Action id="1596">Immunomodulator</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-01-30T16:01:30.000Z</LastModificationDate><ChangeDateLast>2019-02-01T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="16268" linkType="Company"&gt;Vifor Pharma&lt;/ulink&gt; (formerly &lt;ulink linkID="18671" linkType="Company"&gt;OM Laboratories&lt;/ulink&gt;) has developed and launched OM-89, an immunomodulatory protein extract from E coli [&lt;ulink linkID="219967" linkType="reference"&gt;219967&lt;/ulink&gt;]. The drug is indicated as Subreum for the treatment of rheumatoid arthritis [&lt;ulink linkID="219967" linkType="reference"&gt;219967&lt;/ulink&gt;]. The drug is indicated as Uro-Vaxom for the treatment of urinary tract  infections (UTIs) [&lt;ulink linkID="172874" linkType="reference"&gt;172874&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 1993, Subreum was launched in Germany for the treatment of rheumatoid arthritis [&lt;ulink linkID="219967" linkType="reference"&gt;219967&lt;/ulink&gt;]. OM-89 had also been launched as Uro-Vaxom for the treatment of urinary tract  infections (UTIs) [&lt;ulink linkID="172874" linkType="reference"&gt;172874&lt;/ulink&gt;]. In  October 1989,  the drug was approved in Czech Republic [&lt;ulink linkID="1448122" linkType="Reference"&gt;1448122&lt;/ulink&gt;] and was subsequently launched [&lt;ulink linkID="1444818" linkType="Reference"&gt;1444818&lt;/ulink&gt;]. In April 2003, the drug was approved in Belgium [&lt;ulink linkID="1449666" linkType="Reference"&gt;1449666&lt;/ulink&gt;]. By December 2013, the drug had been launched in Argentina, Kazakhstan and the Ukraine [&lt;ulink linkID="1533521" linkType="Reference"&gt;1533521&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;OM Pharma was previously developing the drug, for the treatment of bacterial prostatitis and   chronic pelvic pain syndrome by OM Laboratories [&lt;ulink linkID="1554608" linkType="Reference"&gt;1554608&lt;/ulink&gt;]. However, by November 2015, no development had been reported.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In  October 1989,  the drug was approved in Czech Republic [&lt;ulink linkID="1448122" linkType="Reference"&gt;1448122&lt;/ulink&gt;] and was subsequently launched [&lt;ulink linkID="1444818" linkType="Reference"&gt;1444818&lt;/ulink&gt;]. In April 2003, the drug was approved in Belgium [&lt;ulink linkID="1449666" linkType="Reference"&gt;1449666&lt;/ulink&gt;]. By December 2013, the drug had been launched in Argentina, Kazakhstan and the Ukraine [&lt;ulink linkID="1533521" linkType="Reference"&gt;1533521&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In January 2013,  licensee &lt;ulink linkID="1037068" linkType="Company"&gt;China Medical System&lt;/ulink&gt; is investigating this product in China [&lt;ulink linkID="1357659" linkType="Reference"&gt;1357659&lt;/ulink&gt;]; in August 2013, a clinical trial application was being planned [&lt;ulink linkID="1488608" linkType="Reference"&gt;1488608&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Urinary tract  infection&lt;/subtitle&gt;In April 2005, clinical data from a long-term multicenter, double-blind study of OM-89 in 453 female patients with recurrent UTIs, were published. Patients were treated with one daily capsule of either OM-89 (n = 231) or placebo (n = 222), over a 3-month period. Patients were then administered three 10-day boosters in months 7 to 9 of the trial and observed for 3 months. OM-89 achieved a 34% reduction in the mean rate of UTI episodes compared to placebo. Administration of OM-89 reduced the total duration of UTI and  the severity of symptoms [&lt;ulink linkID="619772" linkType="Reference"&gt;619772&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;In an open and uncontrolled study, the efficacy of Subreum was demonstrated in the treatment of rheumatoid arthritis. Following this first study, two placebo-controlled, randomized, six-month studies, completed by 1996, showed that Subreum induces significant reductions in disease activity in rheumatoid arthritis, causing no more side effects than DMARDS. The protein extract has proved to be as effective as d-penicillamine and auranofin in a number of comparative trials [&lt;ulink linkID="213436" linkType="reference"&gt;213436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bacterial prostatitis and   chronic pelvic pain syndrome&lt;/subtitle&gt;In May 2014,  data from a multicenter, randomized, double-blind, placebo-controlled, parallelâ€“group study  in patients (n = 203) with chronic bacterial prostatitis and chronic pelvic pain syndrome were presented at the 109th AUA Meeting in Orlando, FL. A total of 181 and 155 patients were included for full analysis (FAS and per protocol set (PPS). At the end of the second treatment period, the responder rate (primary endpoint) was 67 and 64% for OM-89 and placebo, respectively in the FAS group; the values were 72.7 and 64.1% for OM-89 and placebo, respectively in the PPS group [&lt;ulink linkID="1554608" linkType="Reference"&gt;1554608&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;OM-89 enhanced the production of cytokines by human peripheral blood mononuclear cells, and stimulated murine phagocytotic activity and natural killer cell activity. Repeated administration induced bacteria-specific serum immunoglobulin responses against the bacterial strains used for preparation of the protein extract [&lt;ulink linkID="307026" linkType="reference"&gt;307026&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><ExpertReview>&lt;para&gt;Dr Paresh Jobanputra, Department of Medicine (WGH), &lt;ulink linkType="Company" linkID="20572"&gt;University of Edinburgh&lt;/ulink&gt;, Rheumatic Diseases Unit, Western General Hospital, Edinburgh. UK.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;28 November 1996&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;Subreum is a bacterial extract obtained by fractionating the alkaline hydrolysate of 18 selected E Coli strains, which yields a glycoprotein with acidic peptides and high molecular weight proteins (10-300 kDa).  The preparation is largely free of bacterial endotoxin (less than 0.1 ng/mg of the active principle) and has a high content of aspartate, glutamate and low amounts of arginine, lysine and glutamine.  The biological activity of subreum may be attributed, in part, to lipopeptides [&lt;ulink linkType="reference" linkID="205317"&gt;205317&lt;/ulink&gt;] as well as to murein and to protein-I (porin) which are both common constituents of Gram negative bacteria [&lt;ulink linkType="reference" linkID="205170"&gt;205170&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;Laboratory studies with murine spleen lymphocytes show that similar bacterial extracts induce antibody formation in vitro by means of a polyclonal B cell activation and, when injected into mice, also enhance specific immune responses to defined antigens [&lt;ulink linkType="reference" linkID="205317"&gt;205317&lt;/ulink&gt;].  An anti-tumor effect, presumed to be due to macrophage stimulation, has also been shown [&lt;ulink linkType="reference" linkID="205323"&gt;205323&lt;/ulink&gt;], as has an increased expression of adhesion molecules on leukocytes [&lt;ulink linkType="reference" linkID="205300"&gt;205300&lt;/ulink&gt;].  Subreum is immunogenic and antibodies to its components have been demonstrated after oral dosing in mice [&lt;ulink linkType="reference" linkID="205303"&gt;205303&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Studies with isolated peripheral blood mononuclear cells from normal human subjects and patients with rheumatoid arthritis show that subreum augments the release of IL-2 [&lt;ulink linkType="reference" linkID="205309"&gt;205309&lt;/ulink&gt;], gamma-interferon, TNFalpha, and IL-1beta when used in the presence of mitogens but not alone [&lt;ulink linkType="reference" linkID="205306"&gt;205306&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In diabetic prone BB rats, subreum, injected ip, delayed the development of spontaneous diabetes but oral or sub-cutaneous treatment was of no benefit.  Cotton pellet granuloma formation in Wistar rats was inhibited by subreum [&lt;ulink linkType="reference" linkID="205167"&gt;205167&lt;/ulink&gt;] although a similar effect was also obtained with indomethacin.  Similarly, oral subreum, at a dose of 4 mg/kg, reduced paw swelling induced by avridine in Wistar rats but a dose of 40 mg/kg had no such effect [&lt;ulink linkType="reference" linkID="205164"&gt;205164&lt;/ulink&gt;].  Tolerance to subreum develops with repeated exposure and prior exposure to subreum appears to improve its efficacy when used to treat avridine-induced arthritis.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Data on metabolism have not been reported in the literature&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;Oral therapy has not been associated with toxicity in animals although weight loss has been noted after ip injection in rats [&lt;ulink linkType="reference" linkID="205323"&gt;205323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt; &lt;br/&gt;Phase I&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Results of phase I studies are not available in the literature&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;A dose ranging study in rheumatoid arthritis indicated that a dose of 6 mg is less effective than either a dose of 24 mg or 48 mg.  Both higher doses have equivalent efficacy on disease activity [&lt;ulink linkType="reference" linkID="205286"&gt;205286&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;Two placebo-controlled, double-blind, randomized studies of six months duration, in rheumatoid arthritis, are reported in the literature.  Both were multi-center studies involving a number of the same investigators and were almost identical in design and analysis.  In both, patients received subreum at an oral dose of 24 mg.  In one study 95 patients were recruited of whom 23 dropped out for various reasons. After six months, despite only comparing 40 and 32 patients in the active and placebo groups respectively, statistically significant improvements in joint tenderness scores, pain, and grip strength were recorded in favor of subreum [&lt;ulink linkType="reference" linkID="205326"&gt;205326&lt;/ulink&gt;].  In another report, involving 107 patients of whom 96 completed the study, subreum improved joint tenderness and swelling, and joint pain, but not grip strength, compared with placebo [&lt;ulink linkType="reference" linkID="205333"&gt;205333&lt;/ulink&gt;].  Neither study showed an advantage of subreum over placebo in improving ESR.&lt;/para&gt;&lt;para&gt;A study of 146 patients from 20 centers, comparing 24 mg subreum with 6 mg of auranofin, showed no important differences between the two drugs in terms of benefit after six months [&lt;ulink linkType="reference" linkID="205334"&gt;205334&lt;/ulink&gt;].  A comparison of subreum with d-penicillamine (500 mg), in a single centre, showed that eight of the 20 patients starting subreum failed to complete 12 months of study and ten of 20 patients on d-penicillamine also failed to complete 12 months [&lt;ulink linkType="reference" linkID="205319"&gt;205319&lt;/ulink&gt;].  D-penicillamine was more effective than subreum in improving swollen and tender joint counts, despite the small numbers, although as with the placebo controlled studies all patients had improved by the end of the study.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;Gastrointestinal symptoms, such as vomiting, were the most common adverse effects reported.  Others included dermatitis, urticaria, sweating, loss of taste and thrombocytopenia.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;CURRENT OPINION&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;It is not possible, from the available literature, to fully appraise the potential of subreum in treating rheumatoid disease.  Comparisons with placebo, and with auranofin, in small numbers of patients, suggest a modest efficacy after six months of treatment.  The drug appears to be very well tolerated and the side-effect profile certainly favors subreum over other agents.  Thus a niche may be found in the treatment of 'mild' disease, although, the efficacy data are relatively unconvincing.  The theoretical basis for the use of subreum is interesting and, if at least part of its mechanism of action is immune enhancement, it is reassuring to note that disease activity is not increased by its use.  It is unlikely that subreum will find a place in more progressive forms of rheumatoid disease except, perhaps, when choices are limited.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1533521" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="KZ">Kazakhstan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1533521" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1533521" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16268">Vifor Pharma Ltd</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2009-09-08T00:00:00.000Z</StatusDate><Source id="1040133" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037068">China Medical System Holdings Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2013-01-17T00:00:00.000Z</StatusDate><Source id="1357659" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18671">OM Pharma</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2015-11-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18671">OM Pharma</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2015-11-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>1989-10-31T00:00:00.000Z</StatusDate><Source id="1448122" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2008-04-01T00:00:00.000Z</StatusDate><Source id="901714" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901714" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901714" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901714" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901714" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>1992-12-01T00:00:00.000Z</StatusDate><Source id="172874" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901714" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1993-11-01T00:00:00.000Z</StatusDate><Source id="219967" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2008-04-30T00:00:00.000Z</StatusDate><Source id="901679" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2008-05-01T00:00:00.000Z</StatusDate><Source id="901714" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="CZ">Czech Republic</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><Source id="1444818" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate>2003-04-22T00:00:00.000Z</StatusDate><Source id="1449666" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate>2014-05-17T00:00:00.000Z</StatusDate><Source id="1554608" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18671">OM Pharma</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2014-05-17T00:00:00.000Z</StatusDate><Source id="1554608" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1037068">China Medical System Holdings Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16266">Vifor Pharma Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><Deals><Deal id="129540" title="Astellas to distribute and promote OM PHARMA's Uro-Vaxom in Russia and CIS territories"/><Deal id="143519" title="CMS to commercialize Vifor Pharma's Uro-Vaxom in People's Republic of China, excluding Hong Kong, Macau and Taiwan  "/><Deal id="172970" title="Distribution of Uro-Vaxom for recurrent urinary tract infections in the Russian and CIS markets"/></Deals><PatentFamilies><PatentFamily id="1442283" number="WO-2008109667" title="Bacterial extract for digestive or urinary tract disorders and process for its preparation"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Medical System Holdings Ltd" id="1037068"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vifor Pharma Group" id="16266"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>